In patients with locally spread melanoma, does staging with 18F-fluorodeoxyglucose positron emission tomography and brain magnetic resonance imaging change the initial treatment plan?

Not Applicable

• Conditions: Melanoma - In transit / satellite metastasis; Cancer - Malignant melanoma

• Registration Number: ACTRN12614000546651
• Lead Sponsor: Prof. John Francis Thompson

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-05-22
• Study Completion: 2015-11-04
• Last Update Posted: 5 July 2021

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Patients with cutaneous melanoma and clinically or pathologically confirmed satellite or in-transit metastasis (N2c) without clinical evidence of metastases elsewhere (stage IIIB, C).

Exclusion Criteria

Clinical evidence of nodal or distant metastasis at time of enrolment.
Previous satellite or in-transit metastasis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients with change of disease management.[After completion of staging with whole body 18F-fluorodeoxyglucose PET/CT and brain MRI.]

Secondary Outcome Measures

Name	Time	Method
Change of AJCC stage.[After completion of staging with whole body 18F-fluorodeoxyglucose PET/CT and brain MRI.];18F-FDG PET/CT and brain MRI sensitivity and specificity.[After completion of staging with whole body 18F-fluorodeoxyglucose PET/CT and brain MRI.];Subgroup analysis on the effect of the number of in transit metastases or satellites on change of management[After completion of staging with whole body 18F-fluorodeoxyglucose PET/CT and brain MRI.]